RAPID-I logo

RAPID-I

Phase IIb, randomised, double-blind, placebo-controlled, mulit-centre trial of infliximab with transcriptomic biomarker and mech

RAPID-I

Phase IIb, randomised, double-blind, placebo-controlled, mulit-centre trial of infliximab with transcriptomic biomarker and mech
Funding NIHR Efficacy and Mechanism Evaluation Programme (EME)
Portfolio Clinical Specialties
Interventions Medicine
Randomised Yes
Status Recruiting
Start Date 24-Apr-2019

Acute pancreatitis is a serious condition in which the pancreas becomes inflamed and is damaged. It causes intense abdominal pain and may lead to multiple organ failure. Those suffering from the disease may need help with breathing, heart and kidney function. One in twenty patients with acute pancreatitis dies, which is more likely to happen to those who develop organ failure. Treatment can be prolonged, often with extended stays in hospital of many weeks. To date many drugs have been tested to treat acute pancreatitis, but none cure the illness or accelerate recovery. This study tests a drug called infliximab, which is made from natural protein and is currently used to treat bowel and joint disease. Infliximab works by blocking an important process in the progression of the disease. This process leads to inflammation in both the pancreas and other parts of the body. The study also looks to see if there are any links between genes and the development of acute pancreatitis, and to see if there are any links between the genes and the way infliximab works. This may help target the right treatment to the right patients and help gain understanding of how infliximab works. If infliximab is beneficial in the treatment of acute pancreatitis, major improvements will be possible in the health of a large number of NHS patients, patient suffering and hospital waiting times will be reduced, and significant savings will be made to NHS costs.

Our latest tweets
View all